In the REVERSAL trial (Reversal of Atherosclerosis with Aggressive Lipid Lowering) in human subjects, in spite of 39% reductions in apoB with atorvastatin and lack of disease progression as assessed by percentage changes in atheroma volume using intravascular ultrasound [111], there was significant increase in oxPL contents in apoB-containing lipoproteins (48%), and malondialdehyde contents in apoB-containing lipoproteins (21%) [112]. This evidence concerns the gene APOB and atherosclerosis.